UPDATE: Piper Jaffray Downgrades Osiris Therapeutics on DFU Data
In a report published on Tuesday, Piper Jaffray analyst Edward A. Tenthoff downgraded Osiris Therapeutics (NASDAQ: OSIR) from Overweight to Neutral and increased the price target on the company from $14 to $21.
In the report, Piper Jaffray stated, "Interim results from the Grafix trial in Diabetic Foot Ulcers (DFUs) met pre-specified stopping rules for overwhelming efficacy. On the primary endpoint, 62% of Grafix patients achieved complete wound closure vs. 21% on standard therapy (p<0.0001). As a result, the blinded phase of the trial is being discontinued immediately, and all patients will now be offered Grafix. Osiris will publish and report these impressive results at upcoming medical meetings and present the data to payors for Grafix reimbursement in DFU. OSIR shares have more than doubled this morning on the news."
Osiris Therapeutics closed on Monday at $10.66.
Latest Ratings for OSIR
|Nov 2015||Brean Capital||Downgrades||Hold||Sell|
|Oct 2015||Brean Capital||Assumes||Hold|
|Dec 2014||Brean Capital||Initiates Coverage on||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.